Calcitriol, lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy

Peritoneal Dialysis International

Volumn 19, Issue SUPPL. 2, 1999, Pages

  Hutchison, Alastair J ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Calcitriol; Calcium; Parathyroid hormone; Phosphorus; Renal osteodystrophy

Indexed keywords

CALCITRIOL; LANTHANUM; PHOSPHATE; PHOSPHATE BINDING AGENT;

CALCIFICATION; CONFERENCE PAPER; HUMAN; HYPERPHOSPHATEMIA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; RISK; SECONDARY HYPERPARATHYROIDISM;

EID: 0033398022     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901902s66     Document Type: Conference Paper

References (35)

1. Nielsen PK, Feldt-Rasmussen U, Olgaard K. A direct effect in vitro of phosphate on PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid cells. Nephrol Dial Transplant. 1996; 9: 1762-9.
2. 3 pulse therapy. Miner Electrolyte Metab. 1995; 21:223-8.
3. Goldsmith DJ, Covic A, Sambrook PA, Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: A retrospective analysis. Nephron. 1997; 77:37-43.
4. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998; 31:607-17.
5. 3? Perit Dial Int. 1989; 9:325-8.
6. Hutchison AJ, Boulton HF, Gokal R. Low-calcium dialysis fluid and oral calcium carbonate in CAPD: A method of controlling hyperphosphataemia whilst minimising aluminium exposure and hypercalcaemia. Nephrol Dial Transplant. 1992; 7:1219-25.
7. Cunningham J, Beer J, Coldwell RD, Noonan K, Sawyer N, Makin HL. Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol. Nephrol Dial Transplant. 1992; 7:63-8.
8. Ackrill P, Day JP, Ahmed R. Aluminum and iron overload in chronic dialysis. Kidney Int. 1988; 24(Suppl 1): S163-7.
9. McGary TJ, Nolph KD, Moore HL, Kartinos NJ. Polycation as an alternative osmotic agent and phosphate binder in peritoneal dialysis. Uremia Invest. 1984-5; 8:79-84.
10. Spengler K, Follmann H, Boos KS, Seidel D, Maywald F. Characterisation and extracorporeal application of a new phosphate-binding agent. Eur J Clin Chem Clin Biochem. 1994; 32:733-9.
11. Passlick J, Wilhelm M, Busch T, Grabensee B, Ohnesorge FK. Calcium alginate, an aluminum free phosphate binder, in patients on CAPD. Clin Nephrol. 1989; 32:96-100.
12. 2 as sole phosphate binder. Nephron. 1992; 60:154-63.
13. Parsons V, Baldwin D, Moniz C, Marsden J, Ball E, Rifkin I. Successful control of hyperparathyroidism in patients on CAPD using magnesium carbonate and calcium carbonate as phosphate binders. Nephron. 1993; 63:379-83.
14. Zimmerman E, Wassmer S, Steudle V. Long-term treatment with calcium-alpha-ketoglutarate corrects hyperparathyroidism. Miner Electrolyte Metab. 1996; 22: 196-9.
15. Riedel E, Hampl H, Steudle V, Neudel M. Calcium alpha-ketoglutarate administration to malnourished haemodialysis patients improves plasma arginine concentrations. Miner Electrolyte Metab. 1996; 22:119-22.
16. Macia M, Coronel F, Navarro JF, Gallego E, Herrero JA, Mendez ML, et al. Calcium salts of keto-amino acids, a phosphate binder alternative for patients on CAPD. Clin Nephrol. 1997; 48:181-4.
17. Bro S, Rasmussen RA, Handberg J, Olgaard K, Feldt-Rasmussen B. Randomized crossover study comparing the phosphate binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. Am J Kidney Dis. 1998; 31:257-62.
18. Kuroda S, Komori M, Nagamatsu K, Ninomiya R, Maejima K, Hasegawa K, et al. Effect of iron as a new type of phosphate binder in hemodialysis patients. Nippon Jinzo Gakkai Shi. 1995; 37:468-73.
19. Graff L, Burnel D. Reduction of dietary phosphorus absorption by oral phosphorus binders. Res Commun Mol Pathol Pharmacol. 1995; 90:389-401.
20. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, et al. Poly[allylamine hydrochloride] (RenaGel): A noncalcaemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis. 1997; 29:66-71.
21. Graff L, Burnel D. A possible non-aluminum oral phosphate binder? A comparative study on dietary phosphorus absorption. Res Commun Mol Pathol Pharmacol. 1995; 90:373-88.
22. Hutchison AJ, Speake M, Dewberry K, Fox JS, Stewart J, Murray JR, Gokal R. Lanthanum carbonate: A novel non-calcium containing phosphate binder in CAPD patients [Abstract]. Perit Dial Int. 1998; 18(Suppl 2):S38.
23. Dewberry K, Fox JS, Stewart J, Murray JR, Hutchison AJ. Lanthanum carbonate: A novel non-calcium containing phosphate binder [Abstract]. J Am Soc Nephrol. 1997; 8:A2610.
24. Gokal R, Ramos J, Ellis HA, Parkinson I, Sweetman V, Dewar J, et al. Histological renal osteodystrophy, and 25-hydroxycholecalciferol and aluminium levels in patients on CAPD. Kidney Int. 1983; 23:15-21.
25. Delmez J, Fallon M, Bergfeld M, Gearing B, Dougan C, Teitelbaum S. Continuous ambulatory peritoneal dialysis and bone. Kidney Int. 1986; 30:379-84.
26. Schaefer K, Umlauf E, von-Herrath D. Reduced risk of hypercalcaemia for hemodialysis patients by administering calcitriol at night. Am J Kidney Dis. 1992; 19:460-4.
27. Martin KJ, Ballal HS, Domoto DT, Blalock S, Weindel M. Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on CAPD: Preliminary observations. Am J Kidney Dis. 1992; 19:540-5.
28. Joffe P, Cintin C, Ladefoged SD, Rasmussen SN. Pharmacokinetics of 1-alfa-hydroxycholecalciferol after intraperitoneal, intravenous and oral administration in patients undergoing peritoneal dialysis. Clin Nephrol. 1994; 41:364-9.
29. 3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture. Endocrinology. 1985; 117:2114-19.
30. Scanziani R, Dozio B, Bonforte G, Surian M. Effects of calcitriol pulse therapy per os in CAPD patients. In: Khanna R, ed. Advances in Peritoneal Dialysis. Toronto: Peritoneal Dialysis Publications, 1994; 10:270-4.
31. Bechtel U, Mucke C, Feucht HE, Schiffl H, SitterT, Held E. Limitations of pulse oral calcitriol therapy in CAPD. Am J Kidney Dis. 1995; 25:291-6.
32. Romanini D, Gazo A, Bellazzi R, Vincenzi A, Nai M, Santagostino M. Long term effect of oral calcitriol single weekly pulse in CAPD and HD. In: Khanna R, ed. Advances in Peritoneal Dialysis. Toronto: Peritoneal Dialysis Publications, 1994; 10:267-9.
33. Panichi V, Andreini B, De Pietro S, Migliori M, Taccola D, Giovannini L, et al. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure. Clin Nephrol. 1998; 49:245-50.
34. 3 and 22-oxacalcitriol on phosphate and calcium metabolism. Kidney Int. 1993; 43:561-6.
35. Nemeth EF, Bennett SA. Tricking the parathyroid gland with novel calcimimetic agents. Nephrol Dial Transplant. 1998; 13:1923-5.